Analysts Set Edwards Lifesciences Corporation (NYSE:EW) PT at $95.96

Edwards Lifesciences Corporation (NYSE:EW) has been given a consensus recommendation of “Moderate Buy” by the twenty-eight analysts that are currently covering the company, MarketBeat Ratings reports. Nine research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $95.9565.

Several brokerages have recently issued reports on EW. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. Truist Financial set a $89.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 24,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total value of $2,012,160.00. Following the sale, the vice president owned 21,266 shares in the company, valued at $1,782,941.44. This represents a 53.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the sale, the vice president owned 33,934 shares in the company, valued at $2,747,975.32. The trade was a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 74,077 shares of company stock valued at $6,165,444. Corporate insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at $25,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $26,000. Kemnay Advisory Services Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $27,000. True Wealth Design LLC boosted its stake in Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.1%

EW opened at $81.16 on Friday. The business has a 50 day simple moving average of $81.59 and a two-hundred day simple moving average of $81.89. The firm has a market capitalization of $46.79 billion, a price-to-earnings ratio of 44.35, a PEG ratio of 2.11 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. Edwards Lifesciences has a one year low of $65.94 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts predict that Edwards Lifesciences will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.